- Roche will unveil the next generation of core lab and
molecular systems, including a total solution for clinical mass
spectrometry.
- Attendees can experience firsthand how fully integrated
systems and data solutions can streamline lab operations, optimize
resources and expedite care.
- The Roche exhibit booth and Roche Idea Lab series
featuring industry experts will highlight how elevating diagnostics
can lead to more insights and better patient outcomes.
INDIANAPOLIS and CHICAGO, July 25,
2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX:
RHHBY) will showcase a laboratory of the future exhibit at the 2024
Association for Diagnostics & Laboratory Medicine (ADLM)
Scientific Meeting and Clinical Lab Expo, July 28 through August 1 in Chicago. Attendees will have the opportunity
to experience how Roche's growing portfolio of integrated systems
and data solutions optimizes resources and simplifies and
streamlines operations while driving better health outcomes.
"Laboratorians strive to deliver trusted, timely test results to
patients with greater effectiveness and efficiency. Our latest
generation of cobas® solutions are proven to
deliver seamless integration of systems and data to support these
efforts," said Brad Moore, president
and CEO of Roche Diagnostics North America. "We are excited to
share these next-generation solutions, which are the building
blocks for future laboratories, and are eager to partner with our
customers so that they can both do more with less and deliver the
best possible outcomes for patients."
Focusing on key attributes of science-based leadership,
operational simplicity and patient-centric partnership, Roche will
feature its newest innovations in-booth at ADLM, including:
- The future cobas® Mass Spec solution*,
is designed to be a total end-to-end solution for clinical mass
spectrometry testing with the goal of seamless integration into the
routine laboratory.
- The new CCM Vertical is a flexible modular system that
uses lab space effectively and seamlessly integrates into the
existing cobas® connection modules.
- The cobas® liat system brings
gold-standard PCR technology to the point of care, providing
results within 20 minutes across a growing menu of assays, now
including the cobas liat SAR-CoV-2, Influenza A/B & RSV
assay** to test for four common respiratory viruses, all within one
test.
- The cobas® pure integrated solutions
combine clinical chemistry, immunoassay and Ion-Selective Electrode
(ISE) diagnostic testing on a single platform for low- to
mid-volume testing needs.
- The cobas® eplex system, a rapid
syndromic molecular diagnostic solution, has been updated with new
features across all aspects of the workflow process.
- The cobas® 5800 is a compact, fully
automated molecular PCR-testing solution with a comprehensive menu
of assays.
- The cobas® LightCycler® PRO
is a qPCR system designed to deliver accuracy and flexibility to
research and clinical diagnostic laboratories with an improved user
experience.
Roche also will present its full array of navify®
digital solutions, which securely integrate data across care
settings, connecting the healthcare community and accelerating
access to innovation and insights. Our digital solutions enable
confident healthcare decisions and help you drive operational,
clinical and financial value.
With the largest diagnostics installed base worldwide, Roche
provides unrivaled ability to scale access to testing at speed for
those who need it most. The cobas® reagent
portfolio offers the broadest menu on an integrated platform and
includes the Elecsys® Alzheimer's cerebrospinal fluid (CSF) assays,
aiming to more effectively detect and support an Alzheimer's
diagnosis.
Roche will also present eight Roche Idea Lab segments in booth
2003, where experts will discuss topics such as mass spectrometry,
digital solutions, respiratory testing, and the use of
high-medical-value assays when treating Alzheimer's and heart
failure. Scientific industry workshops will include
"Laboratorians' Perspectives on Evaluation and Implementation of
Alzheimer's CSF Assays" and "Making a Subjective Sepsis Diagnosis
More Objective: The Role of AI-based Sepsis Medical Algorithms in
Empowering Healthcare Decisions." For more information about
Roche's participation at ADLM 2024 and Roche Idea Lab programming,
visit ADLM.roche.com.
Featured Roche Idea Lab sessions include:
Tuesday, July 30
Improving Access and Patient Outcomes for Sexually Transmitted
Infections | 11 a.m. CST
This session will delve into innovative strategies for enhancing
patient access to STI testing and shed light on the promising
potential of these approaches to positively impact public health
outcomes.
Barbara Van Der Pol, Ph.D., MPH,
University of Alabama at Birmingham,
and Casey Pinto, Ph.D., NP,
Penn State University
Moving Beyond the Transactional Operation with
navify® Digital Solutions to Unlock New
Possibilities for Better Care | 2:30 p.m.
CST
This session will explore how navify®
cutting-edge algorithms help move beyond transactional operations
to foster a holistic approach for better care with AI.
Peter McCaffrey, M.D.,
University of Texas
Testing for Heart Failure in People with Diabetes – What Do the
New ADA Guidelines Mean for Labs? | 3:30
p.m. CST
This session will discuss how to put the American Diabetes
Association recommendation for heart failure risk monitoring in all
people with diabetes into practice.
Ibrahim A. Hashim, M.Sc., Ph.D.,
C.Sci., FIBMS, DABCC, FAACC, UT Southwestern Medical Center,
Parkland Hospital and Health System
Wednesday, July 31
Advancing Respiratory Testing Across the Continuum of Care |
10:30 a.m. CST
This session will discuss how strategies to improve diagnostic
stewardship for respiratory infections contribute to better patient
care.
David Gaston, M.D., Ph.D., and
Alisha Ezell, MHA,
MLS(ASCP)CM, Vanderbilt Health
Making Patient Impact with Ions: A Conversation on the Medical
Value of Mass Spectrometry | 1 p.m.
CST
This session will feature a conversation on the medical value of
mass spectrometry and provide specific case examples related to
patient outcomes.
Victoria Zhang, Ph.D., MBA,
DABCC, University of Rochester Medical
Center
The Pathway to Growing Your Lab | 2:30 p.m. CST
This session will share ideas on how labs can remain competitive
by utilizing existing capacity and improving access for patients in
support of optimized clinical care.
Steve Serota and Robin
Herbner, Wisconsin Diagnostic Laboratories
Are You Listening? The Black Pregnant Woman's Instincts and
Preeclampsia | 3:30 p.m. CST
This session will discuss the Black woman's experience with
healthcare and the role diagnostics can play in improving outcomes
for preeclampsia patients.
Sarosh Rana, M.D., MPH, FACOG,
University of Chicago Medicine
Current and Future Biomarker Testing Landscape in Alzheimer's
Disease | 4:15 p.m. CST
This session will discuss how the availability of Alzheimer's
biomarkers in CSF and blood is revolutionizing the diagnostic
path.
Leslie Shaw, Ph.D., University of Pennsylvania
*Not currently for sale in the
United States.
**This product has not been cleared
or approved by the Food and Drug Administration (FDA), but has been
authorized for emergency use by the FDA under an Emergency Use
Authorization (EUA) for use by authorized laboratories.
About Roche
Founded in 1896 in Basel,
Switzerland, as one of the first industrial manufacturers of
branded medicines, Roche has grown into the world's largest
biotechnology company and the global leader in in-vitro
diagnostics. The company pursues scientific excellence to discover
and develop medicines and diagnostics for improving and saving the
lives of people around the world. We are a pioneer in personalized
healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care
for each person we partner with many stakeholders and combine our
strengths in Diagnostics and Pharma with data insights from the
clinical practice.
In recognizing our endeavor to pursue a long-term perspective in
all we do, Roche has been named one of the most sustainable
companies in the pharmaceuticals industry by the Dow Jones
Sustainability Indices for the fifteenth consecutive year. This
distinction also reflects our efforts to improve access to
healthcare together with local partners in every country we
work.
Genentech, in the United
States, is a wholly owned member of the Roche Group. Roche
is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected
by law.
For Further Information:
To find more information on Roche and images for media use, please
visit the Roche Media Library.
Roche Diagnostics U.S. Media Relations:
us.mediarelations@roche.com
Onsite at ADLM:
Gina Goodenough
+1-317-734-7171
gina.goodenough@roche.com
Multimedia assets
cobas® Mass Spec solution image
CCM Vertical image
cobas® liat system image
cobas® pure integrated
solutions image
cobas® eplex system image
cobas® 5800 image
cobas® LightCycler® PRO image
View original content to download
multimedia:https://www.prnewswire.com/news-releases/roche-showcases-solutions-for-laboratories-of-the-future-at-the-association-for-diagnostics--laboratory-medicine-2024-clinical-lab-expo-302206616.html
SOURCE Roche Diagnostics
